Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88578888 |
LAW OFFICE ASSIGNED |
LAW OFFICE 124 |
MARK SECTION |
MARK |
http://uspto.report/TM/88578888/mark.png (stylized and/or with design) |
STANDARD CHARACTERS |
NO |
USPTO-GENERATED IMAGE |
NO |
OWNER SECTION (current) |
NAME |
Celgene Corporation |
MAILING ADDRESS |
86 Morris Avenue |
CITY |
Summit |
STATE |
New Jersey |
ZIP/POSTAL CODE |
07901 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
OWNER SECTION (proposed) |
NAME |
Celgene Corporation |
MAILING ADDRESS |
86 Morris Avenue |
CITY |
Summit |
STATE |
New Jersey |
ZIP/POSTAL CODE |
07901 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
CORRESPONDENCE INFORMATION (current) |
NAME |
CAMILLE M. MILLER |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
cmiller@cozen.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
NOT PROVIDED |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
Camille M. Miller |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
cmiller@cozen.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
treginelli@cozen.com |
DOCKET/REFERENCE NUMBER |
CELG-1981US/ |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations for use in the treatment of multiple myeloma, blood disease, cancer, diseases in the fields of oncology, immunology
and inflammation; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
1 |
ALLOWANCE MAIL DATE |
12/17/2019 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
125 |
TOTAL AMOUNT |
125 |
SIGNATURE SECTION |
SIGNATURE |
/Camille M. Miller/ |
SIGNATORY'S NAME |
Camille M. Miller |
SIGNATORY'S POSITION |
Attorney |
DATE SIGNED |
04/15/2020 |
SIGNATORY'S PHONE NUMBER |
2156657273 |
FILING INFORMATION |
SUBMIT DATE |
Wed Apr 15 08:29:55 ET 2020 |
TEAS STAMP |
USPTO/ESU-XX.XXX.XX.XXX-2
0200415082955716507-88578
888-710eeffe1387279bdf2c3
5592c7c158bd11bdb9a692c72
ebd299e41d3786aa1d78-CC-2
9538452-20200415082812191
022 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: ABECMA (stylized and/or with design, see http://uspto.report/TM/88578888/mark.png)
SERIAL NUMBER: 88578888
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Celgene Corporation, having an address of
86 Morris Avenue
Summit, New Jersey 07901
United States
Proposed: Celgene Corporation, having an address of
86 Morris Avenue
Summit, New Jersey 07901
United States
Phone:
Fax:
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 12/17/2019.
For International Class 005:
Current identification: Pharmaceutical preparations for use in the treatment of multiple myeloma, blood disease, cancer, diseases in the fields of oncology, immunology and inflammation;
pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the first extension request.
Correspondence Information (current):
CAMILLE M. MILLER
PRIMARY EMAIL FOR CORRESPONDENCE: cmiller@cozen.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED
Correspondence Information (proposed):
Camille M. Miller
PRIMARY EMAIL FOR CORRESPONDENCE: cmiller@cozen.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): treginelli@cozen.com
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /Camille M. Miller/ Date Signed: 04/15/2020
Signatory's Name: Camille M. Miller
Signatory's Position: Attorney
Signatory's Phone: 2156657273
RAM Sale Number: 88578888
RAM Accounting Date: 04/15/2020
Serial Number: 88578888
Internet Transmission Date: Wed Apr 15 08:29:55 ET 2020
TEAS Stamp: USPTO/ESU-XX.XXX.XX.XXX-2020041508295571
6507-88578888-710eeffe1387279bdf2c35592c
7c158bd11bdb9a692c72ebd299e41d3786aa1d78
-CC-29538452-20200415082812191022